Q-omics provides the consensus-scored IRX6 profile across patient tissues and cancer cell-line models. IRX6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, IRX6 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, IRX6 RNA expression shows 11,958 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KICH, and TGCT as cancer lineages where IRX6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IRX6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IRX6 survival associations across molecular data types. IRX6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IRX6 RNA expression–survival associations across cancer types. High IRX6 expression shows unfavorable associations in BLCA, READ, KIRC and UCS, but favorable associations in MESO and THCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for IRX6 RNA expression.
This table summarizes IRX6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for IRX6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IRX6 shows lower tumor expression in KICH, BRCA, LUAD, KIRC and THCA and higher tumor expression in KIRP. The KICH box plot shows higher IRX6 RNA expression in normal versus tumor tissue (log2 FC = −2.674, t-test p < 0.001).
This table shows molecular features associated with IRX6 in patient tissues and cancer cell lines. In patient samples, IRX6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IRX6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
